Free Trial
→ This document could hand you a shot at $915 every single weekend! (From WealthPress) (Ad) Buy MESO Stock  Free MESO Stock Alerts

Mesoblast (MESO) Financials

Mesoblast logo
$11.04 +0.07 (+0.64%)
As of 12:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Mesoblast

Annual Income Statements for Mesoblast

This table shows Mesoblast's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019 6/30/2018 6/30/2017 6/30/2016
Net Income / (Loss) Attributable to Common Shareholders		 -88 -82 -91 -99 -78 -90 -35 -77 -4.13
Consolidated Net Income / (Loss)		 -88 -82 -91 -99 -78 -90 -35 -77 -4.13
Net Income / (Loss) Continuing Operations		 -88 -82 -91 -99 -78 -90 -35 -77 -4.13
Total Pre-Tax Income 		-88 -82 -92 -100 -87 -99 -66 -90 -91
Total Operating Income		 -79 -89 -98 -118 -75 -80 -75 -90 -119
Total Gross Profit		 -56 -66 -65 -67 -19 -20 -10 -33 -9.72
Total Revenue		 -33 -46 -48 -56 -19 -20 -10 -33 -9.72
Operating Revenue		 -33 -46 -48 -56 -19 -20 -10 -33 -9.72
Total Cost of Revenue		 23 20 17 11 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 23 20 17 11 - - - 0.00 -
Total Operating Expenses		 23 23 33 51 56 60 65 57 109
Research & Development Expense		 25 27 33 53 56 60 66 59 50
Other Operating Expenses / (Income)		 -2.57 -4.25 0.54 -1.56 -0.32 0.33 -1.31 -1.49 -2.71
Total Other Income / (Expense), net		 -8.91 6.57 6.81 19 -13 -18 8.71 -0.13 28
Other Income / (Expense), net		 -8.91 6.57 6.81 19 -13 -18 8.71 -0.13 28
Income Tax Expense		 -0.19 -0.21 -0.24 -0.82 -9.42 -8.96 -31 -13 -87
Basic Earnings per Share		 ($0.09) ($0.11) ($0.13) ($0.16) ($0.15) ($0.18) ($0.08) ($0.19) ($0.01)
Weighted Average Basic Shares Outstanding		 1.14B 814.20M 650.45M 648.70M 583.95M 498.63M 482.64M - -
Diluted Earnings per Share		 ($0.09) ($0.11) ($0.13) ($0.16) ($0.15) ($0.18) ($0.08) ($0.19) ($0.01)
Weighted Average Diluted Shares Outstanding		 1.14B 814.20M 650.45M 648.70M 583.95M 498.63M 482.64M - -
Weighted Average Basic & Diluted Shares Outstanding		 1.14B 814.20M 650.45M 648.70M 583.95M 498.63M 482.64M - -

Quarterly Income Statements for Mesoblast

No quarterly income statements for Mesoblast are available.

Annual Cash Flow Statements for Mesoblast

This table details how cash moves in and out of Mesoblast's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019 6/30/2018 6/30/2017 6/30/2016
Net Change in Cash & Equivalents		 -8.30 11 -76 -113 77 13 -7.55 -35 -28
Net Cash From Operating Activities		 -68 -79 -67 -113 -83 -87 -85 -101 -102
Net Cash From Continuing Operating Activities		 -68 -79 -67 -113 -83 -87 -85 -101 -102
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -68 -79 -67 -113 -83 -87 -85 -101 -102
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00
Net Cash From Financing Activities		 58 89 -8.83 0.07 163 100 78 60 73
Net Cash From Continuing Financing Activities		 58 89 -8.83 0.07 163 100 78 65 73
Repayment of Debt		 -12 -0.57 -61 - -0.51 -1.61 -0.39 0.00 0.00
Issuance of Debt		 0.00 0.00 52 - 0.51 44 32 0.00 0.00
Issuance of Common Equity		 65 89 0.21 - 145 30 41 62 69
Other Financing Activities, net		 3.82 1.12 0.02 0.07 18 27 6.17 3.31 4.47
Cash Interest Received		 1.78 0.80 0.01 0.02 0.55 0.73 0.37 0.48 1.13
Cash Income Taxes Paid		 -0.00 -0.02 0.02 - 0.01 0.00 0.03 0.00 0.00

Quarterly Cash Flow Statements for Mesoblast

No quarterly cash flow statements for Mesoblast are available.

Annual Balance Sheets for Mesoblast

This table presents Mesoblast's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019 6/30/2018 6/30/2017
Total Assets		 669 669 662 745 734 652 692 656
Total Current Assets		 86 82 70 148 137 63 101 64
Cash & Equivalents		 63 71 60 137 129 50 38 46
Accounts Receivable		 21 7.00 4.40 4.84 1.57 4.06 50 3.74
Prepaid Expenses		 2.55 3.34 4.99 6.50 5.65 8.04 13 14
Plant, Property, & Equipment, net		 1.11 1.36 2.05 3.02 2.29 0.83 1.08 1.81
Plant, Property & Equipment, gross		 1.11 1.36 2.05 3.02 2.29 0.83 1.08 1.81
Total Noncurrent Assets		 582 586 590 593 595 589 590 590
Intangible Assets		 576 577 579 581 582 583 585 586
Other Noncurrent Operating Assets		 5.85 9.22 12 13 13 5.64 5.68 1.92
Total Liabilities & Shareholders' Equity		 662 661 657 742 731 652 692 656
Total Liabilities		 189 168 165 163 184 171 146 139
Total Current Liabilities		 73 42 51 94 90 44 24 37
Short-Term Debt		 14 5.95 5.02 53 32 14 0.00 -
Accounts Payable		 7.07 20 23 20 25 13 19 22
Other Current Liabilities		 48 10 21 21 33 7.26 5.08 15
Total Noncurrent Liabilities		 116 126 114 69 94 127 122 102
Long-Term Debt		 100 103 92 41 57 67 59 0.00
Capital Lease Obligations		 1.95 3.67 7.09 8.49 6.32 0.00 - -
Other Noncurrent Operating Liabilities		 11 17 13 17 28 58 43 53
Total Equity & Noncontrolling Interests		 480 502 497 581 549 481 546 517
Total Preferred & Common Equity		 480 502 497 581 549 481 546 517
Total Common Equity		 480 502 497 581 549 481 546 517
Common Stock		 1,311 1,249 1,165 1,163 1,051 910 889 830
Retained Earnings		 -909 -821 -739 -648 -549 -470 -380 -345
Other Equity Adjustments		 78 74 71 66 47 41 37 31

Quarterly Balance Sheets for Mesoblast

No quarterly balance sheets for Mesoblast are available.

Annual Metrics And Ratios for Mesoblast

This table displays calculated financial ratios and metrics derived from Mesoblast's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019 6/30/2018 6/30/2017 6/30/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 26.67% 4.50% 14.95% -199.29% 7.40% -101.12% 69.15% -236.18% 0.00%
EBITDA Growth		 -7.36% 10.36% 8.07% -14.05% 11.54% -49.68% 26.87% 0.67% 0.00%
EBIT Growth		 -7.36% 10.36% 8.07% -14.05% 11.54% -49.68% 26.87% 0.67% 0.00%
NOPAT Growth		 10.64% 9.89% 16.84% -58.55% 7.19% -7.66% 17.09% 24.26% 0.00%
Net Income Growth		 -7.41% 10.35% 7.55% -26.78% 13.21% -154.46% 54.06% -1,761.28% 0.00%
EPS Growth		 15.38% 10.35% 7.55% -10.79% 18.83% -139.58% 60.62% -1,603.54% 0.00%
Operating Cash Flow Growth		 14.19% -17.13% 40.25% -36.73% 5.50% -2.30% 15.51% 1.11% 0.00%
Free Cash Flow Firm Growth		 33.15% -5.95% 43.88% -94.94% -10,424.09% 99.63% 71.64% 0.00% 0.00%
Invested Capital Growth		 -1.82% 1.08% -0.86% 6.07% 1.25% -9.82% 21.03% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.78% 99.74% 99.74% 99.18% 89.22% 90.93% 53.49% 85.15% 4.54%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17.91% -16.40% -16.94% -17.48% -15.13% -17.49% -6.64% -14.86% 0.00%
Cash Return on Invested Capital (CROIC)		 -8.32% -12.40% -11.72% -21.40% -11.38% -0.10% -29.12% -226.89% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -17.91% -16.40% -16.94% -17.48% -15.13% -17.49% -6.64% -14.86% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -18.31% -16.32% -18.38% -17.00% -14.19% -18.67% -6.46% -14.86% 0.00%
Net Operating Profit after Tax (NOPAT)		 -55 -62 -69 -83 -52 -56 -52 -63 -83
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 59.33% 40.87% 275.61% -51.01% -29,713.06% 127.68% 130.09% -57.61% 0.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -88 -82 -92 -100 -87 -99 -66 -90 -91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -88 -82 -92 -100 -87 -99 -66 -90 -91
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.29 1.01 0.58 1.50 2.07 1.07 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1,026.54 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.35 1.00 0.61 1.53 2.13 1.06 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.24 0.22 0.21 0.18 0.17 0.17 0.11 0.00 0.00
Long-Term Debt to Equity		 0.21 0.21 0.20 0.09 0.12 0.14 0.11 0.00 0.00
Financial Leverage		 0.11 0.10 0.02 -0.06 0.00 0.05 -0.02 -0.09 0.00
Leverage Ratio		 1.36 1.33 1.30 1.31 1.34 1.31 1.27 1.27 0.00
Compound Leverage Factor		 1.36 1.33 1.30 1.31 1.34 1.31 1.27 1.27 0.00
Debt to Total Capital		 19.49% 18.30% 17.26% 15.02% 14.85% 14.46% 9.81% 0.00% 0.00%
Short-Term Debt to Total Capital		 2.32% 0.97% 0.84% 7.78% 5.03% 2.49% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 17.17% 17.33% 16.43% 7.24% 9.82% 11.96% 9.81% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 80.51% 81.70% 82.74% 84.98% 85.15% 85.55% 90.19% 100.00% 0.00%
Debt to EBITDA		 -1.32 -1.37 -1.13 -1.03 -1.10 -0.82 -0.90 0.00 0.00
Net Debt to EBITDA		 -0.61 -0.50 -0.47 0.34 0.38 -0.31 -0.33 0.00 0.00
Long-Term Debt to EBITDA		 -1.16 -1.30 -1.08 -0.50 -0.73 -0.68 -0.90 0.00 0.00
Debt to NOPAT		 -2.10 -1.81 -1.51 -1.24 -1.83 -1.44 -1.14 0.00 0.00
Net Debt to NOPAT		 -0.96 -0.66 -0.63 0.41 0.64 -0.55 -0.41 0.00 0.00
Long-Term Debt to NOPAT		 -1.85 -1.72 -1.43 -0.60 -1.21 -1.20 -1.14 0.00 0.00
Altman Z-Score		 -1.92 -0.30 -1.01 1.56 2.31 0.29 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 1.18 1.95 1.36 1.57 1.51 1.41 4.21 1.73 0.00
Quick Ratio		 1.15 1.87 1.26 1.50 1.45 1.23 3.67 1.35 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -45 -68 -64 -114 -59 -0.56 -151 -532 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 1.69 0.93 0.81 0.48 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 215.86 392.03 450.52 759.20 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 541 551 545 550 518 512 568 469 0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -10 5.88 -4.75 31 6.38 -56 99 469 0.00
Enterprise Value (EV)		 192 550 331 839 1,102 543 0.00 0.00 0.00
Market Capitalization		 139 509 288 874 1,136 513 0.00 0.00 0.00
Book Value per Share		 $0.59 $0.77 $0.77 $1.00 $1.10 $1.00 $1.13 $0.00 $0.00
Tangible Book Value per Share		 ($0.12) ($0.12) ($0.13) $0.00 ($0.06) ($0.21) ($0.08) $0.00 $0.00
Total Capital		 597 614 601 684 645 562 605 517 0.00
Total Debt		 116 112 104 103 96 81 59 0.00 0.00
Total Long-Term Debt		 102 106 99 50 63 67 59 0.00 0.00
Net Debt		 53 41 43 -34 -34 31 22 -46 0.00
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -36 -26 -37 -30 -50 -18 39 -19 0.00
Debt-free Net Working Capital (DFNWC)		 27 46 23 107 79 32 77 27 0.00
Net Working Capital (NWC)		 13 40 18 54 46 18 77 27 0.00
Net Nonoperating Expense (NNE)		 32 20 22 16 26 34 -17 14 -79
Net Nonoperating Obligations (NNO)		 60 49 48 -32 -31 31 22 -48 0.00
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.89) $0.00 ($1.31) ($1.18) ($1.45) ($0.61) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 1.14B 101.78M 0.00 81.09M 72.99M 62.33M 60.33M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.09) ($0.89) ($1.13) ($1.31) ($1.18) ($1.45) ($0.61) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 1.14B 101.78M 81.31M 81.09M 72.99M 62.33M 60.33M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.31) ($1.18) ($1.45) ($0.61) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.14B 101.78M 81.31M 81.09M 72.99M 62.33M 60.33M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -55 -62 -69 -83 -52 -56 -52 -63 -40
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mesoblast

No quarterly metrics and ratios for Mesoblast are available.

Frequently Asked Questions About Mesoblast's Financials

When does Mesoblast's financial year end?

According to the most recent income statement we have on file, Mesoblast's fiscal year ends in June. Their fiscal year 2024 ended on June 30, 2024.

How has Mesoblast's net income changed over the last 8 years?

Mesoblast's net income appears to be on an upward trend, with a most recent value of -$87.96 million in 2024, rising from -$4.13 million in 2016. The previous period was -$81.89 million in 2023. See where experts think Mesoblast is headed by visiting Mesoblast's forecast page.

What is Mesoblast's operating income?
Mesoblast's total operating income in 2024 was -$79.23 million, based on the following breakdown:
  • Total Gross Profit: -$56.45 million
  • Total Operating Expenses: $22.78 million
How has Mesoblast revenue changed over the last 8 years?

Over the last 8 years, Mesoblast's total revenue changed from -$9.72 million in 2016 to -$33.44 million in 2024, a change of 244.2%.

How much debt does Mesoblast have?

Mesoblast's total liabilities were at $188.80 million at the end of 2024, a 12.7% increase from 2023, and a 35.9% increase since 2017.

How much cash does Mesoblast have?

In the past 7 years, Mesoblast's cash and equivalents has ranged from $37.76 million in 2018 to $136.88 million in 2021, and is currently $62.96 million as of their latest financial filing in 2024.

How has Mesoblast's book value per share changed over the last 8 years?

Over the last 8 years, Mesoblast's book value per share changed from 0.00 in 2016 to 0.59 in 2024, a change of 59.0%.


Related Companies

This page (NASDAQ:MESO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...
GoldenCrest Metals | Sponsored
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored